Form 4: Anixa Biosciences Director Acquires Stock Options

Lewis H. Titterton Jr., a director of Anixa Biosciences, Inc., was granted employee stock options for 25,000 shares on January 2, 2025.

Summary

• On January 2, 2025, Lewis H. Titterton Jr., a director of Anixa Biosciences, Inc., acquired employee stock options for 25,000 shares.
• The options have an exercise price of $2.37.
• The options were granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
• The options vest in twelve equal monthly installments beginning January 31, 2025, and expire on January 2, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock options can be seen as a positive sign of aligning management interests with shareholders, but it's a routine event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a common practice of granting stock options to company directors as part of their compensation package. It's typical for biotech companies to use stock options to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a common practice in the biotechnology industry, used to incentivize executives and align their interests with shareholders.
• The vesting schedule of twelve equal monthly installments is fairly standard.
• The exercise price of $2.37 would need to be compared to the market price of ANIX stock at the time of the grant to assess its value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• Existing shareholders may experience dilution if the options are exercised.

Key Dates